Drug Interactions between duloxetine and Priftin
This report displays the potential drug interactions for the following 2 drugs:
- duloxetine
- Priftin (rifapentine)
Interactions between your drugs
No interactions were found between duloxetine and Priftin. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
duloxetine
A total of 634 drugs are known to interact with duloxetine.
- Duloxetine is in the drug class serotonin-norepinephrine reuptake inhibitors.
-
Duloxetine is used to treat the following conditions:
- Anxiety
- Back Pain
- Bipolar Disorder (off-label)
- Chronic Fatigue Syndrome (off-label)
- Chronic Pain
- Depression
- Diabetic Peripheral Neuropathy
- Fibromyalgia
- Generalized Anxiety Disorder
- Hot Flashes (off-label)
- Major Depressive Disorder
- Osteoarthritis
- Pain (off-label)
- Peripheral Neuropathy (off-label)
- Persistent Depressive Disorder (off-label)
- Small Fiber Neuropathy (off-label)
- Somatoform Pain Disorder (off-label)
- Urinary Incontinence (off-label)
Priftin
A total of 498 drugs are known to interact with Priftin.
- Priftin is in the drug class rifamycin derivatives.
- Priftin is used to treat the following conditions:
Drug and food/lifestyle interactions
rifapentine food/lifestyle
Applies to: Priftin (rifapentine)
ADJUST DOSING INTERVAL: Administration with food may increase the oral bioavailability of rifapentine and reduce the incidence of gastrointestinal adverse events. Administration with a high fat meal typically increases rifapentine's maximum concentration (Cmax) and systemic exposure (AUC) by approximately 40% to 50% over that observed when rifapentine is administered under fasting conditions. Rifapentine is often prescribed in combination with isoniazid. When single doses of rifapentine (900 mg) and isoniazid (900 mg) were administered with a low fat, high carbohydrate breakfast, the Cmax and AUC of rifapentine increased by 47% and 51%, respectively. On the other hand, isoniazid's Cmax and AUC decreased by 46% and 23%, respectively.
MANAGEMENT: Products containing oral rifapentine as the sole ingredient recommend administration with a meal to increase bioavailability and reduce the occurrence of gastrointestinal upset, nausea, and/or vomiting. Consultation of product labeling for combination products and/or relevant guidelines may be helpful if rifapentine is combined with a medication that is typically taken on an empty stomach.
References (2)
- (2021) "Product Information. Isoniazid/Rifapentine 300 mg/300 mg (Macleods) (isoniazid-rifapentine)." Imported (India), 2
- (2021) "Product Information. Priftin (rifapentine)." sanofi-aventis
DULoxetine food/lifestyle
Applies to: duloxetine
GENERALLY AVOID: Use of duloxetine in conjunction with chronic alcohol consumption may potentiate the risk of liver injury. Duloxetine alone can increase serum transaminase levels. In clinical trials, 0.3% of patients discontinued duloxetine due to liver transaminase elevations. The median time to detection was about two months. Three duloxetine-treated patients had liver injury as manifested by transaminase and bilirubin elevations, with evidence of obstruction. Substantial intercurrent ethanol use was present in each of these cases, which may have contributed to the abnormalities observed. Duloxetine does not appear to enhance the central nervous system effects of alcohol. When duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
MANAGEMENT: Due to the risk of liver injury, patients prescribed duloxetine should be counseled to avoid excessive use of alcohol. Duloxetine should generally not be prescribed to patients with substantial alcohol use.
References (1)
- (2004) "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.